Krystal Biotech, Inc. 8K

Krystal Biotech announced strong Q2 2026 financial results driven by VYJUVEK revenue growth, reaffirmed its solid cash position, and detailed extensive global commercialization and late-stage development plans across its genetic medicines pipeline, including 2026–2027 data and registrational trial milestones.

Krystal Biotech, Inc. reported strong second quarter 2026 results and provided a broad business update, highlighted by $119.2 million in global VYJUVEK net product revenue (up 24% year-over-year) with 95% gross margin, net income of $54.8 million, and a robust balance sheet with $1.1 billion in cash and investments, while outlining continued global commercialization progress for VYJUVEK (including planned launches in Spain and Italy and additional regulatory filings), multiple upcoming clinical readouts across its ophthalmology, respiratory, dermatology, and oncology gene therapy pipeline, and issuing full-year 2026 non-GAAP combined R&D and SG&A expense guidance of $175–195 million alongside plans for several registrational trial starts in 2027.

Filing Facts

CIK

1711279

Ticker

KRYS

Form

8K

Source Type

fda

Accession

0001711279-26-000058

Alert Tier

6